Notice of Proposed Sale · 144
Aardvark Therapeutics, Inc.
AARDNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- AARDVARK THERAPEUTICS INC
- Issuer CIK
- 0001774857
- SEC file number
- 001-42513
- Phone
- 858-225-7696
- Person for whose account securities are to be sold
- NELSON SUN
- Relationships to issuer
- Officer
- Street
- 4370 La Jolla Village Drive Suite 1050
- City
- San Diego
- State / country code
- CA
- Postal code
- 92122
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 42,843 | 210,787.56 | 21,884,846 | 09/10/2026 | NASDAQ | Morgan Stanley Smith Barney LLC Executive Financial Services |
Broker / market maker — proposed row 1, entry 1
- Name
- Morgan Stanley Smith Barney LLC Executive Financial Services
- Street
- 1 New York Plaza
- Street (continued)
- 8th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10004
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 09/09/2025 | Open Market Purchase | Issuer | 2,000 | N | 09/09/2025 | N/A |
| Common | 09/26/2024 | Previously Exercised Options | Issuer | 33,842 | N | 09/26/2024 | Cash |
| Common | 05/01/2024 | Series C Preferred | Issuer | 7,001 | N | 05/01/2024 | N/A |
Prior-sale reporting
- Nothing to report for the preceding three months
- Y
Remarks
The 33,842 securities to be sold were acquired upon the vesting of previously exercised options on 09/26/2024 and 11/30/2024.
Notice signature
- Notice date
- 09/10/2026
- Signed
- /s/ Nelson Sun
- Plan adoption dates
- 06/11/2026
Company context
Aardvark is a clinical-stage biopharmaceutical company developing novel, small-molecule therapeutics designed to suppress hunger for the treatment of Prader-Willi Syndrome and metabolic diseases. Hunger, which is the discomfort from not having eaten recently, is a distinct neural signaling pathway separate from appetite, the reward-seeking desire for food. Our programs explore therapeutic applications in hunger-associated indications and potential complementary uses with anti-appetite therapies. For more information, visit www.aardvarktherapeutics.com.